Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II StudyQing Wei, Jieer Ying, Weijun Chen et al.|The Oncologist|2024Cited by 10
Peptide-binding induced inhibition of chemokine CXCL12Hongyang Duan, Yanlian Yang|RSC Advances|2017Cited by 3
Sensitive and dynamic CTCs measurement for prediction and monitoring of PD-1 therapy in GC/EGJC patients: Results from a pilot phase 2 study.Qing Wei, Jingjing Li, Qi Xu et al.|Journal of Clinical Oncology|2021Cited by 0